Prestige Consumer Healthcare (NYSE:PBH) Stock Rating Lowered by StockNews.com

StockNews.com lowered shares of Prestige Consumer Healthcare (NYSE:PBH - Free Report) from a strong-buy rating to a buy rating in a research note published on Tuesday.

Other equities analysts have also recently issued research reports about the company. DA Davidson restated a neutral rating and issued a $65.00 price objective on shares of Prestige Consumer Healthcare in a report on Thursday, May 16th. TheStreet raised Prestige Consumer Healthcare from a c+ rating to a b- rating in a research report on Monday, February 12th. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the company's stock. According to data from MarketBeat, Prestige Consumer Healthcare currently has a consensus rating of Moderate Buy and a consensus target price of $91.25.

Prestige Consumer Healthcare Stock Up 0.5 %

PBH stock traded up $0.35 during trading hours on Tuesday, reaching $65.05. 304,878 shares of the stock were exchanged, compared to its average volume of 246,006. The company has a market cap of $3.25 billion, a price-to-earnings ratio of 15.60, a PEG ratio of 1.83 and a beta of 0.53. The firm's 50-day moving average is $70.49 and its 200-day moving average is $65.35. Prestige Consumer Healthcare has a 12 month low of $55.96 and a 12 month high of $75.31. The company has a debt-to-equity ratio of 0.68, a current ratio of 3.20 and a quick ratio of 2.02.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last announced its earnings results on Tuesday, May 14th. The company reported $1.02 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.14 by ($0.12). The firm had revenue of $277.00 million during the quarter, compared to analyst estimates of $287.42 million. Prestige Consumer Healthcare had a net margin of 18.60% and a return on equity of 13.48%. The firm's quarterly revenue was down 3.1% compared to the same quarter last year. During the same period in the prior year, the business posted $1.07 EPS. On average, equities research analysts expect that Prestige Consumer Healthcare will post 4.41 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the stock. GAMMA Investing LLC bought a new position in shares of Prestige Consumer Healthcare during the fourth quarter worth approximately $25,000. Provence Wealth Management Group bought a new stake in shares of Prestige Consumer Healthcare in the third quarter valued at about $26,000. Pacer Advisors Inc. grew its stake in shares of Prestige Consumer Healthcare by 85.7% in the fourth quarter. Pacer Advisors Inc. now owns 442 shares of the company's stock valued at $27,000 after acquiring an additional 204 shares in the last quarter. Principal Securities Inc. acquired a new stake in Prestige Consumer Healthcare in the 4th quarter worth about $29,000. Finally, ORG Partners LLC acquired a new position in shares of Prestige Consumer Healthcare during the 4th quarter worth approximately $36,000. Institutional investors and hedge funds own 99.95% of the company's stock.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.